Meeting
2020 Genitourinary Cancers Symposium
Real-world prognostic model for overall survival (OS) in patients (pts) with advanced urothelial cancer (aUC) treated with immune checkpoint inhibitors (ICI).
Authors
Ali Raza Khaki
University of Washington, Seattle, WA
Ali Raza Khaki , Leonidas Nikolaos Diamantopoulos , Natalie J. Miller , Mehmet Asim Bilen , Victor Sacristan Santos , Rafael Morales-Barrera , Michael Edward Devitt , Ariel Ann Nelson , Evan Shreck , Hussein Assi , Roubini Zakopoulou , Alejo Rodriguez-Vida , Mark Lythgoe , Alexandra Drakaki , Monika Joshi , Pedro Isaacsson Velho , Lucia Alonso , Matt D. Galsky , Guru Sonpavde , Petros Grivas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 447)
Abstract #
447
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Evolving treatment landscape in metastatic urothelial carcinoma (mUC) post-avelumab maintenance approval: Real-world insights from The US Oncology Network.
First Author: Haojie Li
Poster
2022 ASCO Genitourinary Cancers Symposium
Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).
First Author: Gregory E. Sanda
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee
Poster
2021 ASCO Annual Meeting
Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.
First Author: Rafee Talukder